Request a quote
Request a quote
Global API sourcing simplified
We connect API buyers and suppliers worldwide with speed, trust, and full transparency.

Filters

Filters
Filter
Custom request?
Type
Production region
Qualifications
Show more
Country of origin

Novobiocin API Manufacturers & Suppliers

1 verified results
Get full market intelligence report
Get full market intelligence report
Full access. Full negotiation power All Novobiocin data. Full access. Full negotiation power
€399,-
Get my report Get my report

Commercial-scale Suppliers

United States

Producer
Produced in  United States
|
Audit Report: Click here for more information on Eurofins audit reports
Certifications: USDMF
|
CoA

All certificates

USDMF
CoA
Request a quote Request a quote
Take control of your API sourcing
Submit a Special Inquiry and have Pharmaoffer activate verified suppliers.
Start a Special Inquiry Get full access
Get full market intelligence report
Get full market intelligence report
€399,-
All Novobiocin data. Full access. Full negotiation power
Get my report Get my report
When insight is your advantage
Full data, full access, full negotiation power
Get full access Get full access
Total market transparency Total market transparency
|
Supplier trade data access Supplier trade data access
|
Buyer / supplier flow comparison Buyer / supplier flow comparison
Trusted by 30,000+ registered pharma professionals:
Reach multinationals, SMEs, compounding pharmacies & more!
Procaps
Pfizer
Reckitt
Sanofi
Blau
Abbvie

Novobiocin | CAS No: 303-81-1 | GMP-certified suppliers

A medication that treats infections caused by staphylococci and other susceptible bacteria, supporting specialized therapeutic needs where targeted antibacterial activity is required.

Therapeutic categories

AminocoumarinsAnti-Bacterial AgentsAnti-Infective AgentsBCRP/ABCG2 InhibitorsBenzopyransCarbohydrates
Generic name
Novobiocin
Molecule type
small molecule
CAS number
303-81-1
DrugBank ID
DB01051
Approval status
Approved drug, Investigational drug, Vet_approved drug, Withdrawn drug

Primary indications

  • For the treatment of infections due to staphylococci and other susceptible organisms

Product Snapshot

  • Small-molecule antibiotic API suitable for oral or parenteral formulations
  • Used against staphylococcal infections and other susceptible bacterial pathogens
  • Has mixed regulatory status, with historical approvals and veterinary use in some regions and withdrawal from several major markets

Clinical Overview

Novobiocin is an aminocoumarin antibiotic derived from Streptomyces niveus and structurally related to coumarin glycosides. It was historically used for the treatment of serious infections caused by susceptible Staphylococcus aureus when alternative, less toxic options were unsuitable. The sodium salt was first approved in 1964; however, it was later withdrawn in the United States for reasons related to safety or effectiveness. Despite this, novobiocin maintains relevance in research settings and selected veterinary contexts.

Its antibacterial activity stems from potent inhibition of the GyrB subunit of bacterial DNA gyrase. Novobiocin acts as a competitive inhibitor of the ATPase reaction, blocking the energy transduction required for DNA supercoiling and replication. This mechanism defines the aminocoumarin class, which also includes coumermycin A1 and clorobiocin. Activity is primarily directed toward gram‑positive organisms, including staphylococci.

Pharmacokinetic data are limited in contemporary literature. Novobiocin is known to be orally bioavailable, undergoes hepatic metabolism, and is excreted partly in the urine. Protein binding is high, and tissue distribution is moderate. Specific metabolic pathways and transporter interactions remain incompletely characterized, although the compound is recognized as an inhibitor of several uptake and efflux transporters, including OAT1, OAT3, OATP1B1, OATP1B3, and ABCG2.

Safety limitations historically included gastrointestinal intolerance, hypersensitivity reactions, and concerns about hepatotoxicity. The availability of more effective and better‑tolerated agents also contributed to its discontinuation in clinical practice. Resistance can occur through alterations in the GyrB target site, reducing binding affinity.

Novobiocin has been marketed under various regional brands during its clinical use period, though most human formulations are no longer commercially available.

For API procurement, sourcing should focus on verified manufacturers with demonstrated control of impurity profiles associated with aminocoumarin fermentation products. Regulatory status varies by region, and procurement teams should ensure alignment with current local market authorizations and quality standards.

Identification & chemistry

Generic name Novobiocin
Molecule type Small molecule
CAS 303-81-1
UNII 17EC19951N
DrugBank ID DB01051

Pharmacology

SummaryNovobiocin is an aminocoumarin antibiotic that inhibits the GyrB subunit of bacterial DNA gyrase, blocking ATP‑dependent energy transduction required for DNA topology management. Its activity centers on competitive inhibition of the enzyme’s ATPase function, disrupting DNA replication and transcription processes. Primary targets include DNA gyrase subunit B and, to a lesser extent, DNA topoisomerase I, supporting its use against susceptible staphylococci and related organisms.
Mechanism of actionNovobiocin is an aminocoumarinthat works by inhibiting the GyrB subunit of the bacterial DNA gyrase enzyme involved in energy tranduction. Similar to other aminocoumarin antibiotics, it acts as a competitive inhibitor of the ATPase reaction catalysed by GyrB.
PharmacodynamicsNovobiocin is an aminocoumarin antibiotic that was produced by the actinomycete <i>Streptomyces niveus</i>. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. Other antibiotics in the aminocoumarin class include coumermycin A1 and clorobiocin.
Targets
TargetOrganismActions
DNA gyrase subunit BStaphylococcus aureusinhibitor
DNA topoisomerase 1Staphylococcus aureusinhibitor

ADME / PK

AbsorptionOral bioavailability is negligible.
Half-life6 hours
Protein binding95%

Formulation & handling

  • Low aqueous solubility may necessitate solubilizing excipients or salt forms for oral or parenteral formulations.
  • Solid aminocoumarin structure can show limited chemical stability in solution, so reconstitution and storage conditions should minimize hydrolysis.
  • Moderate lipophilicity supports oral delivery, but crystalline solid handling may require milling to improve dissolution performance.

Regulatory status

Novobiocin is a type of Antibacterials


Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.

Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.

Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.

The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.

As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.

In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.

Novobiocin API manufacturers & distributors

Compare qualified Novobiocin API suppliers worldwide. We currently have 1 companies offering Novobiocin API, with manufacturing taking place in 1 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.

SupplierTypeCountryProduct originCertificationsPortfolio
Producer
United States United States CoA, USDMF30 products

When sending a request, specify which Novobiocin API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).

Use the list above to find high-quality Novobiocin API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.

We show synonyms and CAS numbers for Novobiocin API to help you connect with the right supplier. However, a synonym or CAS number does not always mean it is exactly the same specification. Always confirm the final specs directly with the supplier before placing an order.

Frequently asked questions about Novobiocin API


Sourcing

Which documents are typically required when sourcing Novobiocin API?
Request the core API documentation set: USDMF (1 company), CoA (1 company). Confirm versions and validity dates match the destination market to avoid delays in qualification.
Which manufacturers are known to produce Novobiocin API?
Known or reported manufacturers for Novobiocin: . Evaluate their GMP history, scale, and regional coverage before requesting dossiers or allocating demand.
How can I request quotes for Novobiocin API from GMP suppliers?
Submit quote requests through the supplier listings with your specs and required documents (specifications, target volume, delivery timeline, and destination). Providing consistent details upfront speeds comparable offers and clarifies technical feasibility.
Is a GMP audit report available for Novobiocin manufacturers?
Audit reports may be requested for Novobiocin: 1 GMP audit report available. Confirm the scope and recency of any audit before relying on it for qualification decisions.
How many suppliers offer Novobiocin API on Pharmaoffer?
Reported supplier count for Novobiocin: 1 verified suppliers. Filter listings by certifications, regions, and delivery options to match your qualification plan.
Which countries are known to manufacture Novobiocin API?
Production countries reported for Novobiocin: United States (1 producer). Knowing the manufacturing geography helps anticipate logistics lead times and import compliance needs.
Which certifications do suppliers of Novobiocin usually hold?
Common certifications for Novobiocin suppliers: USDMF (1 company), CoA (1 company). Always verify issuing authorities and expiry dates when reviewing audit packages.

Technical

What is Novobiocin (CAS 303-81-1) used for?
Novobiocin is an aminocoumarin antibiotic historically used to treat serious infections caused by susceptible Staphylococcus aureus when other options were unsuitable. Its current use is largely restricted to research and certain veterinary applications due to withdrawal from human clinical practice. It acts by competitively inhibiting the GyrB ATPase activity of bacterial DNA gyrase, blocking DNA supercoiling and replication.
Which therapeutic class does Novobiocin fall into?
Novobiocin belongs to the following therapeutic categories: Aminocoumarins, Anti-Bacterial Agents, Anti-Infective Agents, BCRP/ABCG2 Inhibitors, Benzopyrans. This positioning helps teams compare alternative APIs, anticipate pharmacology expectations, and align early research priorities.
What conditions is Novobiocin mainly prescribed for?
The primary indications for Novobiocin: For the treatment of infections due to staphylococci and other susceptible organisms. These use cases frame the target patient populations and help prioritize formulation and safety evaluations.
How does Novobiocin work?
Novobiocin is an aminocoumarinthat works by inhibiting the GyrB subunit of the bacterial DNA gyrase enzyme involved in energy tranduction. Similar to other aminocoumarin antibiotics, it acts as a competitive inhibitor of the ATPase reaction catalysed by GyrB.
What should someone know about the safety or toxicity profile of Novobiocin?
Novobiocin’s safety profile historically included gastrointestinal intolerance, hypersensitivity reactions, and reports of hepatotoxicity, which contributed to its withdrawal from routine human use. It also inhibits several drug transporters, creating potential for clinically relevant interactions. Resistance can emerge through GyrB alterations, reducing its effectiveness. Careful control of impurities is important when sourcing the API due to its fermentation‑derived origin.
What are important formulation and handling considerations for Novobiocin as an API?
Novobiocin has low aqueous solubility, so formulations may require solubilizing excipients, salt forms, or particle‑size reduction to enhance dissolution. Its aminocoumarin structure shows limited stability in solution, making controlled reconstitution and storage conditions important to reduce hydrolysis. As a crystalline, moderately lipophilic solid, milling or other physical processing may be needed to achieve suitable performance in oral or parenteral products.
Is Novobiocin a small molecule?
Novobiocin is classified as a small molecule. That classification shapes process design, impurity profiling, and analytical control strategies.
Are there special stability concerns for oral Novobiocin?
Oral Novobiocin has low aqueous solubility, so formulations may require solubilizing excipients or salt forms to maintain adequate stability and performance. Its aminocoumarin structure shows limited chemical stability in solution, making it sensitive to hydrolysis. Managing reconstitution and storage conditions helps reduce degradation, and milling of the crystalline solid may be needed to ensure consistent dissolution.

Pharmaoffer

How does Pharmaoffer’s Smart Sourcing Service help with Novobiocin procurement?
Pharmaoffer's Smart Sourcing Service coordinates compliant suppliers, documentation, and competitive quotes for Novobiocin. It centralizes outreach, follow-ups, and document validation to shorten procurement timelines.
Is Novobiocin included in the PRO Data Insights coverage?
PRO Data Insights coverage for Novobiocin: 326 verified transactions across 85 suppliers and 54 buyers worldwide. Use the dataset to benchmark suppliers and monitor regulatory activity where available.
Where can I access the API market report for Novobiocin?
Market report availability for Novobiocin: Report Available. The report highlights demand trends, pricing drivers, and supplier landscape insights for procurement planning.